|
Pancreatic cancer (pancreatic cancer, PC) is a malignant pancreatic exocrine glands, the incidence rate of 1% to 2% of the common malignant tumors, is one of the human worst prognosis of malignant tumors. Surgery is the only effective treatment means, but due to the lack of specific signs and symptoms of early, early diagnosis is very difficult, most of the patients for treatment when the disease is already advanced, missed the timing of surgery. For advanced pancreatic cancer, chemotherapy is the main treatment, which gemcitabine in 1996 by the U.S. FDA approved for first-line treatment of advanced pancreatic cancer, but its monotherapy did not significantly prolong the survival of patients. High Intensity Focused Ultrasound treatment of solid tumors is a physical means of efficacy and safety in the treatment of advanced pancreatic cancer has been recognized, can significantly improve the clinical benefit response positive rate. In recent years has been for combination therapy clinical studies, but its efficacy outcome measures are not comprehensive. This retrospective analysis of 2001 March to March 2009 in our hospital admitted the 84 cases by clinical or pathological diagnosis of unresectable pancreatic cancer clinical data, divided into high-intensity focused ultrasound group, gemcitabine Bin group and high-intensity focused ultrasound joint gemcitabine gemcitabine group, application Kaplan-Meier method survival analysis was performed to calculate the six months, survival rate and median survival time of 12 months, clinical positive benefit response rate, disease control rate and adverse reaction incidence. Results: The high-intensity focused ultrasound group, gemcitabine group, the joint group of clinical benefit from the positive response rate was 61.1%, 30.0%, 83.3%, pairwise comparisons, all p lt; 0.05, there is significant; disease control rate, respectively, 72.2%, 60.0%, 82.1%, three sets of comparison p gt; 0.05, non-significant; the HIFU group median survival time, 6-month and 12-month survival rates were 7.9 months, 58.2% and 19.1%, respectively, gemcitabine group was 6.4 months, 52.3% and 17.3%, respectively, the combined group to 10.04, 73.8% and 35.2%, pairwise comparisons, joint group higher than the high-intensity focused ultrasound group and gemcitabine He Bin group, both p lt; 0.05 , significant, gemcitabine He Bin group with high intensity focused ultrasound group compared, p gt; 0.05. No significant; III ~ IV degree of hematologic toxicity occurrence rate of the three groups comparison are p gt; 0.05, non-significant. Conclusion: The combined group median survival time, 6-month and 12-month survival rate, clinical benefit response positive rate were higher than the high-intensity focused ultrasound group and gemcitabine group, high intensity focused ultrasound group clinical benefit response positive higher than the gemcitabine group; joint group with high intensity focused ultrasound group and gemcitabine group, the incidence of adverse reactions has not increased. HIFU with gemcitabine combined is expected to become the treatment of unresectable pancreatic cancer an effective and safe means.
|